Topic: Humira
LONDON (Reuters) - Britain's health cost watchdog has changed tack and recommended that rheumatoid arthritis patients should have more options if they do not respond adequately to treatment with a so-called TNF inhibitor drug. The National Institute for Health and Clinical Excellence ...
Abbott Labs profit tops forecasts on greater Humira sales, raises 2009 profit viewAbbott Laboratories said Wednesday it beat its own expectations for the third quarter as sales of its drug Humira continued to climb, along with sales of medical products and nutritional ...
ABBOTT: OUCH! Abbott Laboratories on June 29 earned the dubious honor of being on the losing side of one of the largest patent verdicts in U.S. history. A federal jury ordered the company to pay nearly $1.7 billion to Johnson & Johnson ...
NEW YORK (Reuters) - A U.S. federal jury returned a $1.67 billion verdict against Abbott Laboratories <ABT.N> in a patent suit brought by Johnson & Johnson <JNJ.N> related to arthritis treatments, the drug companies said on Monday. An Abbott spokesman said the ...
New-generation biotech drugs also turn up side effects, safety warnings after hitting marketNearly a fourth of widely used new-generation biological drugs for several common diseases produce serious side effects that lead to safety warnings soon after they go on the market, the ...
